Nymox Announces Appointment of Mark Staples PhD as Vice President of Chemistry, Manufacturing and Controls (CMC)
March 19 2019 - 9:45AM
Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to
announce that Mark Staples PhD has joined Nymox as Vice President
for Chemistry, Manufacturing, and Controls (CMC). Dr Staples is an
expert in the field of biopharmaceutical CMC and will be Nymox's VP
in charge of these activities.
During his career Dr Staples has led innovative
pharmaceutical development teams, supervised successful CMC modules
of regulatory filings for drugs and biologics, managed technology
transfer to production facilities, and functioned in upper
management in a variety of senior positions. Dr Staples held senior
positions with highly successful biopharmaceutical companies such
as Biogen and other well-known corporations. He has extensive
business knowledge and experience in manufacturing, project
management, and regulatory matters in the biopharmaceutical sector.
Marquis Who's Who, presented Dr Staples with the Albert Nelson
Marquis Lifetime Achievement Award in 2018. Dr Staples earned his
PhD in Chemistry from the University of Kansas, and did
post-doctoral work at Harvard Medical School.
Dr Paul Averback, CEO of Nymox, said, "The Nymox
Board and Management are pleased to welcome Dr Staples to the team
as VP heading our chemistry, manufacturing and control (CMC)
activities. Mark is a distinguished expert in the field and has
managed many major projects in his career, including CMC modules of
highly important drug approvals. Dr Staples held senior CMC
positions for many years at Biogen and other well-known companies,
and he has an enviable record of well-known major project
successes. Mark's depth of knowledge and experience with all
aspects of the business will bring considerable added value to the
activities of Nymox and will greatly benefit and strengthen our
organization."
Nymox recently announced the publication of an
important peer review article entitled "Efficacy and Safety of
Fexapotide Triflutate in Outpatient Medical Treatment of Male Lower
Urinary Tract Symptoms Associated with Benign Prostatic
Hyperplasia", authored by Neal Shore MD, Ronald Tutrone MD, and
Claus Roehrborn MD, in Therapeutic Advances in Urology 219, 11,
1-16. The report reviews Fexapotide Triflutate which is Nymox's
first-in-class new molecular approach to managing BPH symptoms.
According to the article, “For many men
suffering from BPH, there remains an unmet need for office- based
treatments for BPH that are effective and that have fewer side
effects and better safety profiles than existing approved molecular
and surgical treatments. Large long-term prospective randomized US
studies of FT have shown statistically significant long-term
improvement in BPH symptoms and objective outcomes including
significant reduction in both spontaneous acute urinary retention
as well as the subsequent incidence of BPH surgery. Based on a
total of >1700 patient treatments including FT and placebo in US
trials to date since 2002, FT has been shown to be well tolerated
with an excellent safety profile. FT is a well-tolerated and
efficacious clinic-based treatment for BPH involving an
intraprostatic injection that requires only a few minutes to
administer, with no catheter nor anesthesia requirements. FT
injection represents a novel, first-in-class BPH treatment
modality”.
The Company will host a shareholder
teleconference on March 25 to update current progress in business
and regulatory submission activities.
For more information please
contact info@nymox.com or 800-936-9669.
Forward Looking Statements
To the extent that statements contained in this
press release are not descriptions of historical facts regarding
Nymox, they are forward-looking statements reflecting the current
beliefs and expectations of management made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995, including statements regarding the need for new options to
treat BPH and prostate cancer, the potential of Fexapotide to treat
BPH and prostate cancer and the estimated timing of further
developments for Fexapotide. Such forward-looking statements
involve substantial risks and uncertainties that could cause our
clinical development program, future results, performance or
achievements to differ significantly from those expressed or
implied by the forward-looking statements. Such risks and
uncertainties include, among others, the uncertainties inherent in
the clinical drug development process, including the regulatory
approval process, the timing of Nymox's regulatory filings, Nymox's
substantial dependence on Fexapotide, Nymox's commercialization
plans and efforts and other matters that could affect the
availability or commercial potential of Fexapotide. Nymox
undertakes no obligation to update or revise any forward looking
statements. For a further description of the risks and
uncertainties that could cause actual results to differ from those
expressed in these forward-looking statements, as well as risks
relating to the business of Nymox in general, see Nymox's current
and future reports filed with the U.S. Securities and Exchange
Commission, including its Annual Report on Form 20-F for the year
ended December 31, 2017, and its Quarterly Reports.
For Further Information
Contact:Erik DanielsenNymox Pharmaceutical
Corporation1-800-93NYMOXwww.nymox.com
Nymox Pharmaceutical (NASDAQ:NYMX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Nymox Pharmaceutical (NASDAQ:NYMX)
Historical Stock Chart
From Apr 2023 to Apr 2024